nodes	percent_of_prediction	percent_of_DWPC	metapath
Norepinephrine—ADRA1B—vas deferens—urinary bladder cancer	0.0999	0.281	CbGeAlD
Norepinephrine—Injection site necrosis—Gemcitabine—urinary bladder cancer	0.0492	0.17	CcSEcCtD
Norepinephrine—Gangrene—Gemcitabine—urinary bladder cancer	0.0236	0.0819	CcSEcCtD
Norepinephrine—Extravasation—Carboplatin—urinary bladder cancer	0.0188	0.0651	CcSEcCtD
Norepinephrine—ADRB3—prostate gland—urinary bladder cancer	0.0155	0.0436	CbGeAlD
Norepinephrine—Extravasation—Mitomycin—urinary bladder cancer	0.014	0.0484	CcSEcCtD
Norepinephrine—SLC18A1—vagina—urinary bladder cancer	0.0137	0.0384	CbGeAlD
Norepinephrine—PAH—renal system—urinary bladder cancer	0.0135	0.0381	CbGeAlD
Norepinephrine—CYP1A2—urine—urinary bladder cancer	0.0115	0.0325	CbGeAlD
Norepinephrine—Lactic acidosis—Epirubicin—urinary bladder cancer	0.0101	0.0351	CcSEcCtD
Norepinephrine—Lactic acidosis—Doxorubicin—urinary bladder cancer	0.00936	0.0324	CcSEcCtD
Norepinephrine—SLC18A2—prostate gland—urinary bladder cancer	0.00884	0.0249	CbGeAlD
Norepinephrine—SLC18A1—lymph node—urinary bladder cancer	0.00883	0.0248	CbGeAlD
Norepinephrine—ADRA1D—prostate gland—urinary bladder cancer	0.00873	0.0246	CbGeAlD
Norepinephrine—ADRB3—female reproductive system—urinary bladder cancer	0.00847	0.0238	CbGeAlD
Norepinephrine—Extravasation—Thiotepa—urinary bladder cancer	0.00703	0.0244	CcSEcCtD
Norepinephrine—Chest pain—Valrubicin—urinary bladder cancer	0.00659	0.0228	CcSEcCtD
Norepinephrine—ADRA1D—epithelium—urinary bladder cancer	0.00641	0.018	CbGeAlD
Norepinephrine—SLC22A2—renal system—urinary bladder cancer	0.00635	0.0179	CbGeAlD
Norepinephrine—ADRB1—prostate gland—urinary bladder cancer	0.00634	0.0178	CbGeAlD
Norepinephrine—SLC22A3—prostate gland—urinary bladder cancer	0.00629	0.0177	CbGeAlD
Norepinephrine—Retrosternal pain—Epirubicin—urinary bladder cancer	0.00613	0.0212	CcSEcCtD
Norepinephrine—ADRA1B—renal system—urinary bladder cancer	0.00608	0.0171	CbGeAlD
Norepinephrine—Extravasation—Gemcitabine—urinary bladder cancer	0.00592	0.0205	CcSEcCtD
Norepinephrine—ADRA1D—urethra—urinary bladder cancer	0.00584	0.0164	CbGeAlD
Norepinephrine—Extravasation—Fluorouracil—urinary bladder cancer	0.00582	0.0202	CcSEcCtD
Norepinephrine—Photophobia—Thiotepa—urinary bladder cancer	0.00576	0.02	CcSEcCtD
Norepinephrine—Retrosternal pain—Doxorubicin—urinary bladder cancer	0.00568	0.0197	CcSEcCtD
Norepinephrine—Extravasation—Cisplatin—urinary bladder cancer	0.00551	0.0191	CcSEcCtD
Norepinephrine—SLC22A3—seminal vesicle—urinary bladder cancer	0.00532	0.015	CbGeAlD
Norepinephrine—Extravasation—Etoposide—urinary bladder cancer	0.00505	0.0175	CcSEcCtD
Norepinephrine—ADRA1A—prostate gland—urinary bladder cancer	0.00501	0.0141	CbGeAlD
Norepinephrine—SLC18A2—female reproductive system—urinary bladder cancer	0.00482	0.0136	CbGeAlD
Norepinephrine—ADRA2C—prostate gland—urinary bladder cancer	0.00478	0.0134	CbGeAlD
Norepinephrine—ADRA1D—female reproductive system—urinary bladder cancer	0.00477	0.0134	CbGeAlD
Norepinephrine—Photophobia—Fluorouracil—urinary bladder cancer	0.00476	0.0165	CcSEcCtD
Norepinephrine—Hypertension—Mitomycin—urinary bladder cancer	0.0046	0.016	CcSEcCtD
Norepinephrine—SLC22A5—prostate gland—urinary bladder cancer	0.00458	0.0129	CbGeAlD
Norepinephrine—SLC22A1—renal system—urinary bladder cancer	0.00449	0.0126	CbGeAlD
Norepinephrine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00446	0.0125	CbGeAlD
Norepinephrine—SLC18A2—vagina—urinary bladder cancer	0.00436	0.0123	CbGeAlD
Norepinephrine—SLC22A3—renal system—urinary bladder cancer	0.00429	0.0121	CbGeAlD
Norepinephrine—SLC22A3—urethra—urinary bladder cancer	0.00421	0.0119	CbGeAlD
Norepinephrine—ADRA2C—seminal vesicle—urinary bladder cancer	0.00404	0.0114	CbGeAlD
Norepinephrine—Vomiting—Valrubicin—urinary bladder cancer	0.00402	0.0139	CcSEcCtD
Norepinephrine—Headache—Valrubicin—urinary bladder cancer	0.00396	0.0137	CcSEcCtD
Norepinephrine—Dyspnoea—Mitomycin—urinary bladder cancer	0.00388	0.0134	CcSEcCtD
Norepinephrine—SLC22A5—seminal vesicle—urinary bladder cancer	0.00387	0.0109	CbGeAlD
Norepinephrine—ADRA2A—prostate gland—urinary bladder cancer	0.00381	0.0107	CbGeAlD
Norepinephrine—ADRA1A—epithelium—urinary bladder cancer	0.00368	0.0104	CbGeAlD
Norepinephrine—ADRB1—female reproductive system—urinary bladder cancer	0.00346	0.00973	CbGeAlD
Norepinephrine—SLC22A3—female reproductive system—urinary bladder cancer	0.00344	0.00966	CbGeAlD
Norepinephrine—ADRA1A—renal system—urinary bladder cancer	0.00342	0.00961	CbGeAlD
Norepinephrine—ADRA2C—renal system—urinary bladder cancer	0.00326	0.00916	CbGeAlD
Norepinephrine—SLC22A1—vagina—urinary bladder cancer	0.00325	0.00914	CbGeAlD
Norepinephrine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00322	0.00907	CbGeAlD
Norepinephrine—ADRA2C—urethra—urinary bladder cancer	0.0032	0.009	CbGeAlD
Norepinephrine—SLC22A5—renal system—urinary bladder cancer	0.00312	0.00877	CbGeAlD
Norepinephrine—SLC22A3—vagina—urinary bladder cancer	0.00311	0.00874	CbGeAlD
Norepinephrine—SLC22A5—urethra—urinary bladder cancer	0.00306	0.00862	CbGeAlD
Norepinephrine—Extravasation—Methotrexate—urinary bladder cancer	0.00303	0.0105	CcSEcCtD
Norepinephrine—SLC6A2—female reproductive system—urinary bladder cancer	0.00294	0.00828	CbGeAlD
Norepinephrine—Extravasation—Epirubicin—urinary bladder cancer	0.00283	0.00981	CcSEcCtD
Norepinephrine—CYP1A2—renal system—urinary bladder cancer	0.00283	0.00795	CbGeAlD
Norepinephrine—SLC18A2—lymph node—urinary bladder cancer	0.00282	0.00794	CbGeAlD
Norepinephrine—Sweating—Gemcitabine—urinary bladder cancer	0.00277	0.00959	CcSEcCtD
Norepinephrine—Vomiting—Mitomycin—urinary bladder cancer	0.00277	0.00959	CcSEcCtD
Norepinephrine—Arrhythmia—Thiotepa—urinary bladder cancer	0.00275	0.00954	CcSEcCtD
Norepinephrine—Headache—Mitomycin—urinary bladder cancer	0.00273	0.00945	CcSEcCtD
Norepinephrine—Extravasation—Doxorubicin—urinary bladder cancer	0.00262	0.00908	CcSEcCtD
Norepinephrine—ADRA2A—urethra—urinary bladder cancer	0.00255	0.00718	CbGeAlD
Norepinephrine—SLC22A5—female reproductive system—urinary bladder cancer	0.0025	0.00703	CbGeAlD
Norepinephrine—Bradycardia—Cisplatin—urinary bladder cancer	0.00246	0.00852	CcSEcCtD
Norepinephrine—ADRA2C—vagina—urinary bladder cancer	0.00236	0.00663	CbGeAlD
Norepinephrine—Hypertension—Thiotepa—urinary bladder cancer	0.00232	0.00802	CcSEcCtD
Norepinephrine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.00232	0.00802	CcSEcCtD
Norepinephrine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.00228	0.00789	CcSEcCtD
Norepinephrine—Anxiety—Thiotepa—urinary bladder cancer	0.00228	0.00788	CcSEcCtD
Norepinephrine—SLC22A5—vagina—urinary bladder cancer	0.00226	0.00635	CbGeAlD
Norepinephrine—Arrhythmia—Cisplatin—urinary bladder cancer	0.00216	0.00748	CcSEcCtD
Norepinephrine—ADRA2A—female reproductive system—urinary bladder cancer	0.00208	0.00585	CbGeAlD
Norepinephrine—SLC22A3—lymph node—urinary bladder cancer	0.00201	0.00565	CbGeAlD
Norepinephrine—Hypertension—Gemcitabine—urinary bladder cancer	0.00195	0.00675	CcSEcCtD
Norepinephrine—Chest pain—Gemcitabine—urinary bladder cancer	0.00192	0.00665	CcSEcCtD
Norepinephrine—Chest pain—Fluorouracil—urinary bladder cancer	0.00189	0.00654	CcSEcCtD
Norepinephrine—ADRA2A—vagina—urinary bladder cancer	0.00188	0.00529	CbGeAlD
Norepinephrine—Anxiety—Cisplatin—urinary bladder cancer	0.00178	0.00618	CcSEcCtD
Norepinephrine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00178	0.00617	CcSEcCtD
Norepinephrine—SLC6A2—lymph node—urinary bladder cancer	0.00172	0.00484	CbGeAlD
Norepinephrine—Hypertension—Etoposide—urinary bladder cancer	0.00166	0.00576	CcSEcCtD
Norepinephrine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00166	0.00575	CcSEcCtD
Norepinephrine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00164	0.00569	CcSEcCtD
Norepinephrine—Chest pain—Etoposide—urinary bladder cancer	0.00164	0.00568	CcSEcCtD
Norepinephrine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00161	0.00559	CcSEcCtD
Norepinephrine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00153	0.0053	CcSEcCtD
Norepinephrine—ADRA2C—lymph node—urinary bladder cancer	0.00153	0.00429	CbGeAlD
Norepinephrine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00152	0.00527	CcSEcCtD
Norepinephrine—SLC22A5—lymph node—urinary bladder cancer	0.00146	0.00411	CbGeAlD
Norepinephrine—Sweating—Methotrexate—urinary bladder cancer	0.00142	0.0049	CcSEcCtD
Norepinephrine—Dyspnoea—Etoposide—urinary bladder cancer	0.0014	0.00486	CcSEcCtD
Norepinephrine—Vomiting—Thiotepa—urinary bladder cancer	0.00139	0.00482	CcSEcCtD
Norepinephrine—Headache—Thiotepa—urinary bladder cancer	0.00137	0.00475	CcSEcCtD
Norepinephrine—Sweating—Epirubicin—urinary bladder cancer	0.00132	0.00459	CcSEcCtD
Norepinephrine—Bradycardia—Epirubicin—urinary bladder cancer	0.00126	0.00438	CcSEcCtD
Norepinephrine—Sweating—Doxorubicin—urinary bladder cancer	0.00123	0.00425	CcSEcCtD
Norepinephrine—ADRA2A—lymph node—urinary bladder cancer	0.00122	0.00342	CbGeAlD
Norepinephrine—Vomiting—Gemcitabine—urinary bladder cancer	0.00117	0.00406	CcSEcCtD
Norepinephrine—Bradycardia—Doxorubicin—urinary bladder cancer	0.00117	0.00405	CcSEcCtD
Norepinephrine—Headache—Gemcitabine—urinary bladder cancer	0.00115	0.004	CcSEcCtD
Norepinephrine—Vomiting—Fluorouracil—urinary bladder cancer	0.00115	0.00399	CcSEcCtD
Norepinephrine—Headache—Fluorouracil—urinary bladder cancer	0.00113	0.00393	CcSEcCtD
Norepinephrine—Arrhythmia—Epirubicin—urinary bladder cancer	0.00111	0.00384	CcSEcCtD
Norepinephrine—Vomiting—Cisplatin—urinary bladder cancer	0.00109	0.00378	CcSEcCtD
Norepinephrine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00103	0.00355	CcSEcCtD
Norepinephrine—Vomiting—Etoposide—urinary bladder cancer	0.001	0.00346	CcSEcCtD
Norepinephrine—Headache—Etoposide—urinary bladder cancer	0.000985	0.00341	CcSEcCtD
Norepinephrine—Chest pain—Methotrexate—urinary bladder cancer	0.000983	0.0034	CcSEcCtD
Norepinephrine—Hypertension—Epirubicin—urinary bladder cancer	0.000932	0.00323	CcSEcCtD
Norepinephrine—Chest pain—Epirubicin—urinary bladder cancer	0.00092	0.00319	CcSEcCtD
Norepinephrine—Anxiety—Epirubicin—urinary bladder cancer	0.000916	0.00317	CcSEcCtD
Norepinephrine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000911	0.00315	CcSEcCtD
Norepinephrine—Hypertension—Doxorubicin—urinary bladder cancer	0.000863	0.00299	CcSEcCtD
Norepinephrine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000852	0.00295	CcSEcCtD
Norepinephrine—Chest pain—Doxorubicin—urinary bladder cancer	0.000851	0.00295	CcSEcCtD
Norepinephrine—Anxiety—Doxorubicin—urinary bladder cancer	0.000848	0.00294	CcSEcCtD
Norepinephrine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00084	0.00291	CcSEcCtD
Norepinephrine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000788	0.00273	CcSEcCtD
Norepinephrine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000786	0.00272	CcSEcCtD
Norepinephrine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000727	0.00252	CcSEcCtD
Norepinephrine—Vomiting—Methotrexate—urinary bladder cancer	0.000599	0.00207	CcSEcCtD
Norepinephrine—Headache—Methotrexate—urinary bladder cancer	0.00059	0.00204	CcSEcCtD
Norepinephrine—Vomiting—Epirubicin—urinary bladder cancer	0.00056	0.00194	CcSEcCtD
Norepinephrine—Headache—Epirubicin—urinary bladder cancer	0.000552	0.00191	CcSEcCtD
Norepinephrine—Vomiting—Doxorubicin—urinary bladder cancer	0.000519	0.0018	CcSEcCtD
Norepinephrine—Headache—Doxorubicin—urinary bladder cancer	0.000511	0.00177	CcSEcCtD
Norepinephrine—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	3.87e-05	0.000109	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	3.85e-05	0.000108	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	3.84e-05	0.000108	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.82e-05	0.000107	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—ESR1—urinary bladder cancer	3.82e-05	0.000107	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.81e-05	0.000107	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	3.77e-05	0.000106	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—SRC—urinary bladder cancer	3.77e-05	0.000106	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.76e-05	0.000106	CbGpPWpGaD
Norepinephrine—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.76e-05	0.000106	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—CREBBP—urinary bladder cancer	3.74e-05	0.000105	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	3.73e-05	0.000105	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—CREBBP—urinary bladder cancer	3.71e-05	0.000104	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	3.69e-05	0.000104	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.67e-05	0.000103	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—FGFR3—urinary bladder cancer	3.67e-05	0.000103	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IGF1—urinary bladder cancer	3.66e-05	0.000103	CbGpPWpGaD
Norepinephrine—ADRA2A—Hemostasis—TP53—urinary bladder cancer	3.65e-05	0.000103	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	3.64e-05	0.000102	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling by GPCR—EGFR—urinary bladder cancer	3.64e-05	0.000102	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—TERT—urinary bladder cancer	3.63e-05	0.000102	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	3.61e-05	0.000102	CbGpPWpGaD
Norepinephrine—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	3.59e-05	0.000101	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	3.58e-05	0.000101	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—ESR1—urinary bladder cancer	3.57e-05	0.0001	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	3.51e-05	9.87e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	3.51e-05	9.86e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	3.5e-05	9.83e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	3.49e-05	9.81e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling by GPCR—KRAS—urinary bladder cancer	3.44e-05	9.67e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.41e-05	9.59e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	3.38e-05	9.49e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—MYC—urinary bladder cancer	3.38e-05	9.49e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—RHOA—urinary bladder cancer	3.35e-05	9.42e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CREBBP—urinary bladder cancer	3.35e-05	9.4e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	3.33e-05	9.37e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	3.33e-05	9.36e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	3.32e-05	9.33e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IGF1—urinary bladder cancer	3.3e-05	9.29e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	3.3e-05	9.28e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—EGFR—urinary bladder cancer	3.3e-05	9.28e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—EGFR—urinary bladder cancer	3.29e-05	9.24e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	3.26e-05	9.17e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	3.26e-05	9.17e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	3.25e-05	9.13e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	3.25e-05	9.12e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	3.24e-05	9.09e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	3.21e-05	9.02e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.18e-05	8.93e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PPARG—urinary bladder cancer	3.16e-05	8.88e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	3.15e-05	8.84e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	3.13e-05	8.81e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CREBBP—urinary bladder cancer	3.13e-05	8.78e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—KRAS—urinary bladder cancer	3.12e-05	8.77e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	3.12e-05	8.76e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	3.11e-05	8.73e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—ERBB2—urinary bladder cancer	3.1e-05	8.72e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IGF1—urinary bladder cancer	3.09e-05	8.68e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.08e-05	8.66e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	3.08e-05	8.65e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—EGFR—urinary bladder cancer	3.07e-05	8.63e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	3.07e-05	8.62e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—PTGS2—urinary bladder cancer	3.06e-05	8.6e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	3.05e-05	8.59e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	3.04e-05	8.54e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	3.04e-05	8.53e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	3.03e-05	8.51e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	3.02e-05	8.5e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	2.99e-05	8.4e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	2.98e-05	8.38e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—CXCL8—urinary bladder cancer	2.94e-05	8.27e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	2.93e-05	8.24e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling by GPCR—HRAS—urinary bladder cancer	2.92e-05	8.22e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	2.9e-05	8.15e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	2.9e-05	8.14e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	2.86e-05	8.03e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	2.84e-05	7.97e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	2.83e-05	7.95e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	2.83e-05	7.95e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	2.81e-05	7.91e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	2.8e-05	7.88e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	2.8e-05	7.87e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	2.79e-05	7.83e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	2.78e-05	7.82e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—TP53—urinary bladder cancer	2.77e-05	7.79e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	2.77e-05	7.78e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	2.74e-05	7.71e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	2.74e-05	7.71e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.73e-05	7.68e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	2.7e-05	7.58e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.69e-05	7.55e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	2.68e-05	7.55e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	2.68e-05	7.54e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—PTEN—urinary bladder cancer	2.67e-05	7.5e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	2.66e-05	7.49e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	2.66e-05	7.48e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	2.66e-05	7.47e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	2.65e-05	7.46e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—HRAS—urinary bladder cancer	2.65e-05	7.45e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.65e-05	7.45e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	2.65e-05	7.44e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	2.64e-05	7.42e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	2.63e-05	7.4e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	2.62e-05	7.37e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	2.62e-05	7.36e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—EP300—urinary bladder cancer	2.62e-05	7.36e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	2.61e-05	7.33e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	2.58e-05	7.24e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	2.57e-05	7.21e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.56e-05	7.2e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	2.56e-05	7.2e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	2.56e-05	7.19e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—EP300—urinary bladder cancer	2.55e-05	7.16e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	2.54e-05	7.14e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.54e-05	7.14e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	2.54e-05	7.13e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	2.52e-05	7.09e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	2.51e-05	7.05e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	2.51e-05	7.05e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	2.5e-05	7.02e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.49e-05	7.01e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	2.49e-05	6.99e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.48e-05	6.98e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	2.48e-05	6.96e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	2.47e-05	6.95e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.47e-05	6.93e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.46e-05	6.92e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	2.45e-05	6.9e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	2.44e-05	6.87e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	2.44e-05	6.87e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—EP300—urinary bladder cancer	2.44e-05	6.86e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.43e-05	6.84e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.43e-05	6.84e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	2.43e-05	6.82e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	2.43e-05	6.82e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.42e-05	6.79e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	2.41e-05	6.78e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	2.4e-05	6.76e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.39e-05	6.73e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	2.39e-05	6.72e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	2.37e-05	6.68e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	2.37e-05	6.67e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	2.37e-05	6.67e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.36e-05	6.65e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	2.36e-05	6.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.36e-05	6.62e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	2.33e-05	6.56e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.33e-05	6.55e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	2.31e-05	6.5e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	2.3e-05	6.46e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	2.3e-05	6.45e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.29e-05	6.43e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	2.29e-05	6.43e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	2.28e-05	6.4e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	2.28e-05	6.4e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	2.25e-05	6.33e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	2.25e-05	6.32e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	2.24e-05	6.31e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	2.24e-05	6.29e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	2.24e-05	6.29e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	2.24e-05	6.29e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	2.23e-05	6.27e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	2.22e-05	6.23e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	2.21e-05	6.21e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.2e-05	6.19e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	2.2e-05	6.18e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	2.2e-05	6.17e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	2.19e-05	6.15e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	2.17e-05	6.1e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	2.17e-05	6.09e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	2.16e-05	6.06e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	2.15e-05	6.05e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.15e-05	6.05e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	2.15e-05	6.05e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	2.13e-05	5.98e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	2.13e-05	5.98e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	2.1e-05	5.9e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	2.09e-05	5.89e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	2.07e-05	5.83e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	2.07e-05	5.82e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—EP300—urinary bladder cancer	2.07e-05	5.81e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	2.04e-05	5.73e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	2.04e-05	5.73e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	2.03e-05	5.71e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.03e-05	5.71e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	2.03e-05	5.69e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	2.02e-05	5.68e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	2.02e-05	5.67e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	2e-05	5.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	2e-05	5.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	1.99e-05	5.58e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.96e-05	5.52e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.96e-05	5.51e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.96e-05	5.51e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.96e-05	5.5e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.95e-05	5.48e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	1.94e-05	5.46e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.93e-05	5.43e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.93e-05	5.42e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.92e-05	5.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.88e-05	5.28e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.88e-05	5.28e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.86e-05	5.23e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	1.85e-05	5.21e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.85e-05	5.2e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	1.83e-05	5.16e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	1.83e-05	5.13e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.82e-05	5.13e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.82e-05	5.11e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	1.81e-05	5.1e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.81e-05	5.1e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.81e-05	5.09e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.81e-05	5.09e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	1.81e-05	5.08e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	1.79e-05	5.02e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.74e-05	4.9e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.73e-05	4.86e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	1.73e-05	4.86e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	1.71e-05	4.82e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	1.69e-05	4.74e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.68e-05	4.73e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.68e-05	4.73e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.68e-05	4.71e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.65e-05	4.63e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.65e-05	4.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	1.63e-05	4.58e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.62e-05	4.56e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.61e-05	4.53e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.59e-05	4.46e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.57e-05	4.42e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	1.56e-05	4.38e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.55e-05	4.37e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	1.54e-05	4.33e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	1.52e-05	4.28e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	1.51e-05	4.23e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	1.5e-05	4.21e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	1.5e-05	4.21e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.47e-05	4.14e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	1.46e-05	4.09e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	1.43e-05	4.03e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	1.39e-05	3.91e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	1.38e-05	3.88e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.37e-05	3.86e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	1.33e-05	3.74e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	1.32e-05	3.72e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	1.27e-05	3.58e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.24e-05	3.48e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.2e-05	3.36e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.18e-05	3.33e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.14e-05	3.21e-05	CbGpPWpGaD
